---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003348"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:10:41.315764+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma appoints new CFO, CMO departs; leadership reshuffled as late-stage program advances

## Summary
- Michael Carulli promoted to CFO; Winston Kung transitions to advisor through March 2024.
- Leila Alland steps down as CMO; remains advisor through March 2024 at $500/hour.
- Deepika Jalota appointed Chief Development Officer; Marc Fellous named SVP Clinical Development.
- Robert Ticktin expands role to include Operations; Tim Smith adds Corporate Development duties.
- Carulli receives $370K base salary, 40% bonus target, and severance policy coverage.

## SEC filing metadata
- accession: 0001193125-24-003348
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312524003348/0001193125-24-003348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312524003348/d104934d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003348
- JSON: https://secwatch.observer/filing/0001193125-24-003348.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003348.txt

## Key facts
- Executive change
  Winston Kung changed role as Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals, Inc..
  - Action: transitioned from his role as COO and CFO
  - Role: Chief Operating Officer and Chief Financial Officer
  source text: On January 5, 2024, the Company also announced that Winston Kung, the Company’s current Chief Operating Officer (“ COO ”) and CFO, will transition from his role as COO and CFO, effective January 4, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312524003348/0001193125-24-003348-index.htm
- Executive change
  Leila Alland changed role as Chief Medical Officer at PMV Pharmaceuticals, Inc..
  - Action: transitioned from her role as CMO
  - Role: Chief Medical Officer
  source text: Also on January 5, 2024, the Company announced that Leila Alland, M.D., the Company’s Chief Medical Officer (“ CMO ”), will transition from her role as CMO, effective on January 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312524003348/0001193125-24-003348-index.htm
- Executive change
  Michael Carulli was appointed as Chief Financial Officer at PMV Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 5, 2024, PMV Pharmaceuticals, Inc. (the “ Company ”) announced the appointment of Michael Carulli as Chief Financial Officer (“ CFO ”), principal financial officer and principal accounting officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312524003348/0001193125-24-003348-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.